期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高级别胶质瘤治疗反应评判的新标准 被引量：7

原文传递
导出
摘要 胶质瘤是成人最常见原发性脑肿瘤，年发病率大约在4～5／10000…。对高级别胶质瘤治疗效果的评价目前主要依据患者生存时间，或是无进展生存时间及影像学缓解率，后者在复发病变中更常用。90年代初Macdonald等。提出了高级别胶质瘤治疗反应的判定标准。
作者 李守巍 江涛
机构地区 北京三博脑科医院 北京神经外科研究所
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第11期1180-1182,共3页 Chinese Journal of Neurosurgery
基金 国家自然科学基金（81302200）
关键词 高级别胶质瘤 治疗反应 标准 原发性脑肿瘤 生存时间 年发病率 治疗效果 缓解率
分类号 R739.4 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献40

  • 1Shai RM, Reichardt JK, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas[ J]. Future Oncol, 2008,4(4) :525 - 534.
  • 2Sanson M. Editorial review: targets for glioma treatment: from bench to bedside [ J ]. Curr Opin Oncol, 2008, 20 (6) : 650 - 651.
  • 3Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma[J]. Nat Clin Pract Oncol, 2008, 5(11) :634-644.
  • 4Brandsma D, de Bruin HG, Bromberg JE, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide [ J ]. Cancer, 2008, 113(2) :405 -410.
  • 5[1]American Cancer Society,American Society.Cancer Facts and Figures 2005.Atlanta:American Cancer Society,2005:1-64.
  • 6[2]Central Brain Tumor Resistry of the United States(2005),Statistical Report:Primary Brain Tumors in the United States.1998-2002.Hinsdale:Central Brain Tumor Registry of the United States.2005:1-15.
  • 7[3]Takano S,Yoshii Y,Kondo S,et al.Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.Cancer Res,1996,56:2185-2190.
  • 8[4]Abdulrauf SI,Edvardsen K,Ho K L.et al.Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.J Neurosurg,1998,88:513-520.
  • 9[7]Willett CG,Boucher Y.di Tomaso E,et al.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med,2004,10:145-147.
  • 10[8]Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med,2005,352:987-996.

共引文献98

同被引文献59

  • 1王凤玮,温玲,朱思伟,姚嫱,蔡玉梅,马刚.结直肠癌组织中突变型Axin2对Wnt信号转导系统的调控及其机制[J].癌症,2007,26(10):1041-1046. 被引量：9
  • 2Reardon DA, Galanis E, DeGroot JF, et ol. Clinical trial end points for high-grade glioma: the evolving landscape [J]. Neuro Oncol, 2011, 13(3): 353-361.
  • 3Chinot OL, Macdonald DR, Abrey LE, et ol. Response assessment criteria for glioblastoma: practical adaptatior and implementation in clinical trials of antiangiogenic therapy [J]. Curr Neurol Neurosci Rep, 2013, 13(5): 347.
  • 4Wen PY, Norden AD, Drappatz J, et al. Response assess.ment challenges in clinical trials of gliomas [J]. Curr Oncol Rep, 2010, 12(1): 68-75.
  • 5Lutz K, Radbruch A, Wiestler B, et al. Neuroradiological response criteria for high-grade gliomas [J]. Clin Neuro- mdiol, 2011, 21(4): 199-205.
  • 6Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [J]. J Clin Oncol, 2010, 28(11): 1963-1972.
  • 7Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically deliver- ed therapies for gliomas: Response Assessment in Neuro- Oncology (RANO) Working Group [J]. Neurosurgery, 2012, 70(1): 234-244.
  • 8Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma [J]. Cancer J, 2012, 18(1): 26- 31.
  • 9Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review [J]. Expert Rev Neurother, 2013, 13(4): 389-403.
  • 10Pouleau HB, Sadeghi N, Baleriaux D, et ol. High levels of cellular proliferation predict pseudoprogression in glioblas- toma patients [J]. Int J Oncol, 2012, 40(4): 923-928.

引证文献7

二级引证文献38

中华神经外科杂志
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部